IGFBPs and breast cancer

Breast Disease

Volumn 17, Issue , 2003, Pages 91-104

  Perks, Claire M ^a   Holly, Jeff M P ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEINASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

BINDING AFFINITY; BREAST CANCER; ENZYME REGULATION; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW;

EID: 0842346651     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2003-17109     Document Type: Review

References (149)

1. M. Parrizas, A.R. Saltiel and D. LeRoith, Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways, J Biol Chem 272(1) (1997), 154-161.
2. J.I. Jones and D.R. Clemmons, Insulin-like growth factors and their binding proteins: biological actions, Endocr Rev 16(1) (1995), 3-34.
3. D.D. De Leon et al., Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells, Growth Factors 6(4) (1992), 327-336.
4. S. Paik, Expression of IGF-I and IGF-II mRNA in breast tissue, Breast Cancer Res Treat 22(1) (1992), 31-38.
5. D. LeRoith et al., Molecular and cellular aspects of the insulin-like growth factor I receptor, Endocr Rev 16(2) (1995), 143-163.
6. V. Papa et al., Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer, Cancer Res 53(16) (1993), 3736-3740.
7. S. Kato et al., Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science 270(5241) (1995), 1491-1494.
8. R.C. Baxter, IGF binding protein-3 and the acid-labile sub-unit: formation of the ternary complex in vitro and in vivo, Adv Exp Med Biol 343 (1993), 237-244.
9. S.M. Twigg and R.C. Baxter, Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit, J Biol Chem 273(11) (1998), 6074-6079.
10. V. Hwa, Y. Oh and R.G. Rosenfeld, The insulin-like growth factor-binding protein (IGFBP) superfamily, Endocr Rev 20(6) (1999), 761-787.
11. D.R. Brigstock et al., Proposal for a unified CCN nomenclature, Mol Pathol 56(2) (2003), 127-128.
12. J.A. Figueroa et al., Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status, J Cell Biochem 52(2) (1993), 196-205.
13. J.C. Chen et al., Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line, J Cell Physiol 158(1) (1994), 69-78.
14. O. Ritvos et al., Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells, Endocrinology 122(5) (1988), 2150-2157.
15. D.R. Clemmons, IGF binding proteins: regulation of cellular actions, Growth Regul 2(2) (1992), 80-87.
16. J.I. Jones et al., Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence, Proc Natl Acad Sci USA 90(22) (1993), 10553-10557.
17. M. Langkamp et al., Intracellular signalling of insulin-like growth factor binding protein-2, Growth Hormone and IGF Research, 2000, pg 138, OC31.
18. L.J. Schedlich et al., Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells, J Biol Chem 273(29) (1998), 18347-18352.
19. S.C. Hodgkinson et al., Glycosaminoglycan binding characteristics of the insulin-like growth factor-binding proteins, J Mol Endocrinol 13(1) (1994), 105-112.
20. C.A. Conover, Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3, Endocrinology 129(6) (1991), 3259-3268.
21. J.I. Jones et al., Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I, J Cell Biol 121(3) (1993), 679-687.
22. D. Yee et al., Identification of insulin-like growth factor binding proteins in breast cancer cells, Breast Cancer Res Treat 18(1) (1991), 3-10.
23. D.R. Clemmons et al., Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status, Endocrinology 127(6) (1990), 2679-2686.
24. M.S. Sheikh et al., Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells, Biochem Biophys Res Commun 183(3) (1992), 1003-1010.
25. F. Pekonen et al., Insulin-like growth factor binding proteins in human breast cancer tissue, Cancer Res 52(19) (1992), 5204-5207.
26. Z.M. Shao et al., IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma, Cancer Res 52(18) (1992), 5100-5103.
27. S.E. McGuire et al., Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues, Cancer Lett 77(1) (1994), 25-32.
28. R.L. Rocha et al., Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival, Clin Cancer Res 3(1) (1997), 103-109.
29. D. Yee, J. Sharma and S.G. Hilsenbeck, Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer, J Natl Cancer Inst 86(23) (1994), 1785-1799.
30. R.L. Rocha et al., Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features, J Natl Cancer Inst 88(9) (1996), 601-606.
31. H. Yu et al., Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer, Br J Cancer 74(8) (1996), 1242-1247.
32. P.F. Bruning et al., Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer, Int J Cancer 62(3) (1995), 266-270.
33. K. Bohlke et al., Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast, Epidemiology 9(5) (1998), 570-573.
34. S.E. Hankinson et al., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet 351(9113) (1998), 1393-1396.
35. K.K. Kaulsay et al., Serum IGF-binding protein-6 and prostate specific antigen in breast cancer, Eur J Endocrinol 140(2) (1999), 164-168.
36. A.J. Stewart et al., Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells, J Biol Chem 265(34) (1990), 21172-21178.
37. A.V. Lee, P. Darbre and R.J. King, Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells, Mol Cell Endocrinol 99(2) (1994), 211-220.
38. P.C. Owens et al., Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells, Biochem Biophys Res Commun 193(2) (1993), 467-473.
39. S.E. Pratt and M.N. Pollak, Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media, Cancer Res 53(21) (1993), 5193-5198.
40. F. Vignon et al., Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture, J. Clinic. Endocrinol. Metab. 56 (1993), 1124-1130.
41. E. Lonning and E.A. Lien, Mechanisms of action of endocrine treatment in breast cancer, Crit Rev Oncol Hematol 21(1-3) (1995), 158-193.
42. P.E. Lonning et al., Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients, Cancer Res 52(17) (1992), 4719-4723.
43. M.N. Pollak, H.T. Huynh and S.P. Lefebvre, Tamoxifen reduces serum insulin-like growth factor I (IGF-I), Breast Cancer Res Treat 22(1) (1992), 91-100.
44. J.B. Lawrence et al., Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins, Clin Cancer Res 3(10) (1997), 1713-1720.
45. S.I. Helle et al., Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients, Int J Cancer 69(4) (1996), 335-339.
46. E.A. Lien et al., Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients, J Steroid Biochem Mol Biol 41(3-8) (1992), 541-543.
47. E. Bajetta et al., The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels, J Steroid Biochem Mol Biol 63(4-6) (1997), 261-267.
48. M.J. Reed et al., The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer, Int J Cancer 52(2) (1992), 208-212.
49. S.I. Helle et al., Influence of treatment with onapristone on the IGF-system in breast cancer patients, J Steroid Biochem Mol Biol 66(3) (1998), 159-163.
50. V.J. Frost et al., Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer, J Clin Endocrinol Metab 81(6) (1996), 2216-2221.
51. Z.S. Gucev et al., Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells, Cancer Res 56(7) (1996), 1545-1550.
52. Y. Oh et al., Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action, J Biol Chem 270(23) (1995), 13589-13592.
53. H. Salahifar, R.C. Baxter and J.L. Martin, Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1, Endocrinology 141(9) (2000), 3104-3110.
54. L.C. Lai et al., Insulin-like growth factor binding protein-3 in breast cyst fluid: relationships with insulin-like growth factors I and II and transforming growth factor-beta 1 and 2, Cancer Lett 110(1-2) (1996), 207-212.
55. Y. Oh, IGF-independent regulation of breast cancer growth by IGF binding proteins, Breast Cancer Res Treat 47(3) (1998), 283-293.
56. D.H. Yang et al., Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and upregulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells, J Clin Endocrinol Metab 83(7) (1998), 2593-2596.
57. C. McCaig et al., Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells, Br J Cancer 86(12) (2002), 1963-1969.
58. S.M. Leal et al., The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor, J Biol Chem 272(33) (1997), 20572-20576.
59. S. Fanayan et al., Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor, J Biol Chem 275(50) (2000), 39146-39151.
60. D.N. Danforth, Jr. and M.K. Sgagias, Tumor necrosis factor alpha enhances secretion of transforming growth factor beta2 in MCF-7 breast cancer cells, Clin ancer Res 2(5) (1996), 827-835.
61. K. Koli and J. Keski-Oja, 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells, Cancer Res 55(7) (1995), 1540-1546.
62. M.R. Mirza, Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients, Cancer Treat Rev 18(2) (1991), 145-148.
63. F. Rozen, J. Zhang and M. Pollak, Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation, Int J Oncol 13(4) (1998), 865-869.
64. Y. Oh et al., Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells, Prog Growth Factor Res 6(2-4) (1995), 503-512.
65. J. Shemer et al., Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid, J Clin Endocrinol Metab 77(5) (1993), 1246-1250.
66. K. Swisshelm et al., Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid, Proc Natl Acad Sci USA 92(10) (1995), 4472-4487.
67. J.L. Martin et al., Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol, Endocrinology 136(3) (1995), 1219-1226.
68. S.Y. James, A.G. Mackay and K.W. Colston, Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells, J Steroid Biochem Mol Biol 58(4) (1996), 395-401.
69. K.W. Colston et al., Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3, J Mol Endocrinol 20(1) (1998), 157-162.
70. F. Rozen et al., Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation, J Natl Cancer Inst 89(9) (1997), 652-656.
71. A. Coutts, L.J. Murphy and L.C. Murphy, Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens, Breast Cancer Res Treat 32(2) (1994), 153-164.
72. H. Huynh, X.F. Yang and M. Pollak, A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780, Cell Growth Differ 7(11) (1996), 1501-1506.
73. H. Huynh, X. Yang and M. Pollak, Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells, J Biol Chem 271(2) (1996), 1016-1021.
74. J.L. Martin, S.M. Weenink and R.C. Baxter, Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases, J Biol Chem 278(5) (2003), 2969-2976.
75. Y. Lu et al., Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin), J Natl Cancer Inst 93(24) (2001), 1852-1857.
76. J.B. Lawrence et al., The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A, Proc Natl Acad Sci USA 96(6) (1999), 3149-3153.
77. W.H. Busby, Jr., et al., The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium, J Biol Chem 275(48) (2000), 37638-37644.
78. S. Mohan et al., ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts, Biochemistry 41(51) (2002), 15394-15403.
79. P. Cohen et al., Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma, J Clin Endocrinol Metab 75(4) (1992), 1046-1053.
80. G. Karazanashvili and P.A. Abrahamsson, Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer, J Urol 169(2) (2003), 445-457.
81. M.L. Hsieh et al., Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D, Cancer Res 57(13) (1997), 2651-2656.
82. A. Magklara et al., Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid, Clin Chem 45(10) (1999), 1774-1780.
83. E.P. Diamandis, Prostate specific antigen-new applications in breast and other cancers, Anti Cancer Res 16(6C) (1996), 3983-3984.
84. H. Yu et al., Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue, Breast Cancer Res Treat 40(2) (1996), 171-178.
85. S. Rehault et al., Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3, Eur J Biochem 268(10) (2001), 2960-2968.
86. H. Yu and H. Berkel, Prostate-specific antigen (PSA) in women, J La State Med Soc 151(4) (1999), 209-213.
87. E.R. Sauter et al., Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk, Cancer Epidemiol Biomarkers Prev 5(12) (1996), 967-970.
88. E.R. Sauter et al., Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer, Cancer Detect Prev 26(2) (2002), 149-157.
89. Q. Yang et al., Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer, Anti Cancer Res 22(3) (2002), 1825-1828.
90. M.P. Look and J.A. Foekens, Clinical relevance of the urokinase plasminogen activator system in breast cancer, Apmis 107(1) (1999), 150-159.
91. F. Descotes et al., Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas, Breast Cancer Res Treat 49(2) (1998), 135-143.
92. P.G. Campbell et al., Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3, Am J Physiol 275(2 Pt 1) (1998), E321-331.
93. P.G. Campbell and D.L. Andress, Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation by IGFBP-5-(201-218), Am J Physiol 273(5 Pt 1) (1997), E996-1004.
94. T.J. Nam, W. Busby, Jr., and D.R. Clemmons, Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I, Endocrinology 138(7) (1997), 2972-2978.
95. C. Lalou, C. Lassarre and M. Binoux, A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin, Endocrinology 137(8) (1996), 3206-3212.
96. H. Rochefort, F. Capony and M. Garcia, Cathepsin D: a protease involved in breast cancer metastasis, Cancer Metastasis Rev 9(4) (1990), 321-331.
97. D.D. De leon et al., Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisense insulin-like growth factor II (IGF-II), Horm Metab Res 31(2-3) (1999), 142-147.
98. M. Mathieu et al., Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II, Mol Endocrinol 4(9) (1990), 1327-1335.
99. V. Cappelletti et al., Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines, Tumour Biol 17(5) (1996), 290-298.
100. C.A. Conover, Insulin-like growth factor binding protein proteolysis in bone cell models, Prog Growth Factor Res 6(2-4) (1995), 301-309.
101. J.A. Coverley and R.C. Baxter, Phosphorylation of insulin-like growth factor binding proteins, Mol Cell Endocrinol 128(1-2) (1997), 1-5.
102. J.I. Jones et al., Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I, Proc Natl Acad Sci USA 88(17) (1991), 7481-7485.
103. J.A. Coverley, J.L. Martin and R.C. Baxter, The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3, Endocrinology 141(2) (2000), 564-570.
104. M.M. Rechler, Insulin-like growth factor binding proteins, Vitam Horm 47 (1993), 1-114.
105. L.A. Bach, N.R. Thotakura and M.M. Rechler, Human insulin-like growth factor binding protein-6 is O-glycosylated, Growth Regul 3(1) (1993), 59-62.
106. S.M. Firth and R.C. Baxter, The role of glycosylation in the action of IGFBP-3, Prog Growth Factor Res 6(2-4) (1995), 223-229.
107. C.M. Perks et al., A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells, Biochem Biophys Res Commun 294(5) (2002), 988-994.
108. S.M. Firth and R.C. Baxter, Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3, J Endocrinol 160(3) (1999), 379-387.
109. W.F. Blum et al., Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I, Endocrinology 125(2) (1989), 766-772.
110. T. Nickerson, H. Huynh and M. Pollak, Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells, Biochem Biophys Res Commun 237(3) (1997), 690-693.
111. S.M. Firth et al., Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells, Biochem Biophys Res Commun 246(2) (1998), 325-329.
112. J.A. Figueroa et al., Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells, J Cell Physiol 157(2) (1993), 229-236.
113. W.L. McGuire, Jr., et al., Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action, J Natl Cancer Inst 84(17) (1992), 1336-1341.
114. D. Yee et al., Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells, Cell Growth Differ 5(1) (1994), 73-77.
115. Y. Oh et al., Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition, J Biol Chem 268(20) (1993), 14964-14971.
116. A.J. Butt et al., Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells, J Biol Chem 275(50) (2000), 39174-39181
117. Z.P. Gill et al., Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner, J Biol Chem 272(41) (1997), 25602-25607.
118. C. A. Fowler et al., Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells, Int J Cancer 88(3) (2000), 448-453.
119. C.M. Perks, C. McCaig and J.M. Holly, Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria, J Cell Biochem 80(2) (2000), 248-258.
120. A.C. Williams et al., Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells, Cancer Res 60(1) (2000), 22-27.
121. A.D. Hollowood et al., IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation, Int J Cancer 88(3) (2000), 336-341.
122. L. Buckbinder et al., Induction of the growth inhibitor IGF-binding protein 3 by p53, Nature 377(6550) (1995), 646-649.
123. R. Rajah, B. Valentinis and P. Cohen, Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism, J Biol Chem 272(18) (1997), 12181-12188.
124. C.M. Perks et al., Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells, J Cell Biochem 75(4) (1999), 652-664.
125. P. Norgaard et al., Transforming growth factor beta and cancer, Cancer Treat Rev 21(4) (1995), 367-403.
126. C. McCaig, C.M. Perks and J.M. Holly, Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin, J Cell Sci 115(Pt 22) (2002), 4293-4303.
127. K.M. Yamada and K. Clark, Cell biology: survival in three dimensions, Nature 419(6909) (2002), 790-791.
128. C.M. Perks et al., Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cellsm, Biochem Biophys Res Commun 294(5) (2002), 995-1000.
129. L.A. Maile et al., The role of cell surface attachment and proteolysis in the insulin-like growth factor (IGF)-independent effects of IGF-binding protein-3 on apoptosis in breast epithelial cells, Endocrinology 140(9) (1999), 4040-4045.
130. A. Parker et al., Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I, Mol Biol Cell 9(9) (1998), 2383-2392.
131. D.L. Andress, Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor, Am J Physiol 274(4 Pt 1) (1998), E744-750.
132. Y. Oh et al., Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells, J Biol Chem 268(35) (1993), 26045-26048.
133. Y. Yamanaka et al., Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule, Endocrinology 140(3) (1999), 1319-1328.
134. J.A. Irving and P.K. Lala, Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGF-beta, IGF-II, and IGFBP-1, Exp Cell Res 217(2) (1995), 419-427.
135. J.I. Jones, M.E. Doerr and D.R. Clemmons, Cell migration: interactions among integrins, IGFs and IGFBPs, Prog Growth Factor Res 6(2-4) (1995), 319-327.
136. C.M. Perks et al., Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells, J Mol Endocrinol 22(2) (1999), 141-150.
137. C. Perks et al., IGFBP-3 modulates integrin signalling independently of IGF-I in Hs578T human breast cancer cells, Growth Hormone and IGF Research 10(4) (2000), A26: O6.4.
138. Y. Gui and L.J. Murphy, Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma, J Clin Endocrinol Metab 86(5) (2001), 2104-2110.
139. Z. Shi et al., ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3, J Biol Chem 275(24) (2000), 18574-18580.
140. T.J. Nam et al., Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth, Endocrinology 141(3) (2000), 1100-1106.
141. B. Perbal, [The CCN family of cell growth regulators: a new family of normal and pathologic cell growth and differentiation regulators: lessons from the first international workshop on CCN gene family], Bull Cancer 88(7) (2001), 645-649.
142. C. McCaig, C. Perks and J. Holly, MAP Kinase inhibitor blocks IGF-independent effect of IGFBP-3 on breast epithelial cell survival and cell attachment, Proceedings of the Endocrine Society's 83rd Annual Meeting, 2001, pp. P2:268.
143. C. McCaig, C.M. Perks and J.M. Holly, Signalling pathways involved in the direct effects of IGFBP-5 on breast epithelial cell attachment and survival, J Cell Biochem 84(4) (2002), 784-794.
144. A.D. Hollowood et al., Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions, J Cell Biochem 86(3) (2002), 583-589.
145. B. Liu et al., Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis, J Biol Chem 275(43) (2000), 33607-33613.
146. A. Sommer et al., Properties of glycosylated and non-glycosylated human recombinant IGF binding protein-3 (IGFBP-3), Growth Regal 3(1) (1993), 46-49.
147. L. Shiry et al., Radiosensitizing effect of rhIGFBP-3 on MCF-7 breast cancer cells in vitro, in Horm Res. 2002, p. 266, abstract 20.
148. Q. Yu et al., Insulin-like growth factor binding protein-3: Single-agent and synergistic effects with chemotherapeutic drugs on solid tumor models, in AACR. 2003. Washington DC, p. 172, abstract 755.
149. E. Ioachim et al., Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression, Eur J Cancer 38(18) (2002), 2362-2370.